Sudarshan Pharma Industries is a Mumbai-based pharmaceutical and specialty chemical maker built on a simple idea: replace what India imports from China by making it at home, from the raw material all the way to the finished pill. Founded in 2008 by brothers Hemal and Sachin Mehta as a specialty chemical trading firm, it has since climbed the value chain into manufacturing active pharmaceutical ingredients, intermediates, and branded generics, listing on the BSE SME Platform in March 2023. The recurring approach is vertical integration - controlling the chemistry from basic building blocks through to the final dosage form - so the company can promise supply security, regulatory-ready documentation, and prices that are not at the mercy of a single overseas supplier.
Business segments
A single integrated pharmaceutical and specialty chemical engine, organised across five deeply connected activities - specialty chemical sourcing, API manufacturing, oncology intermediates, finished formulations, and international trading - all fed by a shared R&D backbone.
1. Specialty chemicals and intermediates: the raw-material foundation
The company sources, distributes, and increasingly makes the high-purity solvents and performance chemicals that pharmaceutical and industrial customers need, using a cost-plus model that protects margins from price swings.
- India's China-dependence problem - roughly 70% of the intermediates India needs for APIs come from China, and for certain categories - antibiotics, vitamins, heterocyclic compounds - the reliance runs between 55% and 85%, exposing domestic manufacturers to supply disruptions and tariff risks. SPIL positions itself as the compliant Indian alternative.
- A portfolio of over 40 molecules - the catalogue spans Acetonitrile, Tetrahydrofuran, 1,4-Dioxane, NMP, Sesamol (for which a patent was filed in April 2026), and dozens of other CAS-numbered intermediates used across pharmaceuticals, paints, adhesives, and agrochemicals.
- Cost-plus, not spot - specialty chemical contracts are structured on a cost-plus formula, so when input prices move, the selling price moves with them, insulating the business from raw-material volatility.
- Approved by the world's buyers - the company has been added to the qualified vendor lists of multinational corporations globally, and its customer roster includes Intas, Minova, Invision Life sciences, Omkar Pharma, SRF, Astral Pipes, DuPont, Reliance, Bayer Corp, and Akzo Nobel, among more than 30 named industrial and pharma majors.
2. API and intermediates manufacturing: the import-substitution engine
This is where the company makes the active pharmaceutical ingredients themselves - most notably Vitamins B1 and B6, which it claims to be the first in India to manufacture under the government's PLI scheme.
- Two vitamins, one basket, first in India - SPIL is the only company with two APIs (Vitamin B1 and Vitamin B6) approved under a single basket of the Production Linked Incentive scheme, with committed investments of Rs. 27 crore and Rs. 59.7 crore respectively and maximum incentives of Rs. 115 crore across both units. The company manufactured both vitamins for the first time in India.
- From root to finished molecule - Vitamin B6 was developed entirely in-house, from basic raw materials through every intermediate to the finished product, and Vitamin B1 has been demonstrated at laboratory scale covering the complete process; patent applications have been filed for the manufacturing processes and intermediates for Vitamin B1, and the company intends to file a patent for the manufacturing process of Vitamin B6 and its intermediates.
- Hyderabad as the manufacturing heart - the Hyderabad unit operates as a bulk-drug and intermediate facility with its own synthetic R&D centre, HPLC lab, and QC wet lab, and holds both GMP certification and ISO 9001:2015 accreditation. In August 2025, the company acquired an additional 1,563-square-metre facility in Medchal, Telangana, with 80 kilolitres of reactor capacity, to produce high-value APIs including Ropivacaine, Bupivacaine, Sitagliptin, Apixaban, and Rivaroxaban.
- A pipeline of nearly 30 APIs - the process R&D pipeline stretches from Trimetazidine and Linagliptin to Oseltamivir and Entecavir, covering cardiovascular, anti-diabetic, anti-viral, and anti-fungal therapies.
- Mahad: the next plant - a new manufacturing unit dedicated to critical APIs currently imported from China is under development and scheduled to be fully operational by March 2026.
3. Oncology APIs and intermediates: the dedicated cancer-chemistry subsidiary
Through its wholly owned subsidiary Ratna Lifesciences, the company operates a specialised manufacturing facility focused exclusively on oncology derivatives - a high-value, low-volume niche with significant barriers to entry.
- Bought, not built from scratch - Ratna Lifesciences was acquired in November 2023 for Rs. 5.5 crore in cash, giving SPIL immediate access to an operational plant, a trained technical team, existing licences, and a standing order book of nearly 2 metric tonnes with revenue potential of Rs. 15 crore.
- Small capacity, expandable footprint - the Ratna Lifesciences facility currently produces 2 metric tonnes per annum, but that capacity can be expanded to 15 metric tonnes; at full utilisation, the plant can generate Rs. 55-60 crore annually. The company is acquiring adjacent MIDC land to multiply capacity roughly tenfold.
- Among the few - Ratna Lifesciences is described as one of only a handful of specialised manufacturers in India producing oncology derivatives and intermediates in a dedicated facility.
- Products already commercialised - the portfolio includes Gemcitabine Hydrochloride, Imatinib Mesylate, Capecitabine Intermediate, Paclitaxel, and Docetaxel, with newer oncology APIs such as Olaparib, Crizotinib, Cisplatin, and Lenalidomide in the pipeline.
4. Finished formulations and branded generics: the patient-facing business
The company makes oral liquids and capsules at its Palghar plant and sells branded and unbranded generics through its own field force across five Indian states, reaching hospitals and retail pharmacies directly.
- A plant built for liquids - the Palghar facility houses a 1,000-litre oral liquid production tank capable of producing 2,000 litres per shift, scalable to 6,000 litres across two shifts, and has received approvals for 50 products covering antibiotics, cough syrups, antipyretics, antifungals, antiallergics, and multivitamins.
- Make-to-order for institutions - the company supplies generic formulations on a make-to-order basis to hospitals and healthcare organisations, including institutional customers such as the Armed Forces Medical Services Depot and Larsen & Toubro's aeronautical division.
- A branded generics field force - an ethical marketing division with over 85 sales executives promotes 96 products, of which 56 are registered under the "R" trademark; top-selling brands include METFOCAL, PULMORELIEF AX, SET DOWN, and JIVAN KIT.
- First-in-India product innovations - the company has launched a mouth-dissolving strip delivery system under the Love Bird brand, a cardiac first-aid kit (HART KIT LD) that provides life-saving drugs for heart attacks, and SET DOWN, a constipation product combining allopathy and ayurveda.
5. Exports and international trading: the global reach
The company sells its own manufactured APIs and formulations into non-regulated markets across Eurasia, Africa, and the Middle East, while also sourcing chemicals from East Asian vendors for Indian customers.
- Non-regulated markets are the focus - exports go primarily to South East Asia, the Middle East, and North Africa, with named destinations including Lebanon, Jordan, UAE, Saudi Arabia, Bangladesh, Nigeria, Ghana, Kenya, and South Africa; in FY26, export turnover reached Rs. 21.85 crore, driven mainly by own-manufactured API and oncology products.
- Indenting as a second revenue stream - the company earns fees by sourcing specialty chemicals, intermediates, and basic solvents from Korea, Taiwan, China, and Japan on behalf of domestic buyers, a business overseen directly by Joint Managing Director Sachin Mehta.
- Registration-led expansion - SPIL is applying for formulation registrations in several African and Asian countries to unlock recurring export orders, and sees an opportunity to open chemical and API warehouses in Congo and Kenya.
- Trade-fair pipeline - at the CPHI 2023 pharmaceutical ingredients exhibition in Delhi, the company received purchase orders estimated at Rs. 40 crore, demonstrating the lead-generation power of its trade-fair presence.
Research and development
A DSIR-approved formulation centre in Dehradun, two university partnerships, and a bioplastic patent form the innovation engine that feeds new molecules and dosage forms into every business line.
- Dehradun as the R&D hub - the company has established a DSIR-approved R&D and formulation development centre in Dehradun, with premises acquired under a five-year rent agreement, and expects to commence operations in March 2025, with work focused on oral, liquid, and injectable dosage forms.
- Amity University partnership - a strategic collaboration with Dr. William Selvamurthy at Amity University's Noida campus covers joint work in nanotechnology, pharmaceutical R&D, patent writing, and commercialisation of innovative technologies.
- Bioplastic technology acquisition - in January 2025, the company acquired exclusive rights for five years to a patent on preparing bioplastic from rice stubble, aloe vera waste, PVA, and glycerol plasticiser, under a technology transfer agreement with Uttaranchal University.
Group structure and partners
The listed parent company sits atop nine subsidiaries - spanning oncology manufacturing, chemical trading, healthcare disposables, and international trading entities in Singapore, Dubai, Poland, and the USA - with promoters holding a 57.39% stake.
- Wholly owned operating subsidiaries - Ratna Lifesciences (oncology manufacturing, Pune), Life Science Chemical (chemical trading, Bharuch, Gujarat), and Sudarshan Pharma Lifescience (pharmaceutical manufacturing, yet to commence operations) are the domestic operating arms.
- International subsidiaries for market access - the group has incorporated entities in Singapore (wholesale chemical trading), Dubai (general trading), Poland (basic chemicals and pharmaceutical wholesale), and the USA (pharmaceuticals and specialty chemicals), with a Canadian subsidiary proposed.
- Board and leadership - the board is chaired by founder Hemal Mehta, with brother Sachin Mehta as Joint Managing Director; independent directors and senior consultants include specialists in GMP regulatory consulting, pharmaceutical R&D, and chemical engineering.